Wednesday , November 22 2017
Home / Therapies / DPP-4 Therapy Center (page 6)

DPP-4 Therapy Center

SGLT2 Inhibitors as Add-On for Poorly Controlled Patients on DPP-4s and Metformin

As the diabetes epidemic continues to grow, practitioners are increasingly searching for medication solutions that can help patients to better manage their diabetes. This month, we have a recent slides series from the ADA showing the positive effects of adding-on SGLT-2 inhibitors to the medication regimen of patients on DPP-4’s …

Read More »

Handbook of Diabetes, 4th Edition, Excerpt #10: Management of Type 2 Diabetes

handbook-of-diabetes-image

Rudy Bilous, MD, FRCP Richard Donnelly, MD, PHD, FRCP, FRACP   Lifestyle modification The starting points and mainstays of treatment for type 2 diabetes are diet and other modifications of lifestyle, such as increasing exercise and stopping smoking (Figure 11.1). The major aims are to reduce the weight of obese patients and …

Read More »

Could Glucagon-like Peptide-1 (GLP-1) Agonists Be Delivered Intranasally?

Possibility of non-subcutaneous administration could increase patient compliance….  GLP-1 agonists are effective therapeutic options for treating diabetes. While their effectiveness has been established, compliance with these medications may be limited in some patients due to their subcutaneous route of administration and gastrointestinal adverse effects. In a recent prospective, double-blind, placebo-controlled …

Read More »

Surprising Trends in the Use of Antidiabetic Drugs

Researchers track data on antidiabetic prescriptions dispensed from retail pharmacies in the US and note some interesting prescribing patterns. What is the most antidiabetic drug dispensed?… See more SGLT-2 Resources Despite the ability of nonpharmacological methods such as lifestyle interventions and bariatric surgery to improve type 2 diabetes outcomes, most …

Read More »

Alternative GLP-1 Delivery Systems

Although glucagon-like peptide-1 (GLP-1) is highly biologically active following intravenous or subcutaneous injection, a non-injectable alternative for activating GLP-1 receptor signaling would clearly be desirable. Studies by Gutniak, Ahren and colleagues in Sweden have shown that GLP-1 formulated in buccal tablets is absorbed into the circulation and lowers blood glucose …

Read More »